Assessment of a poly-epitope candidate vaccine against Hepatitis B, C, and poliovirus in interaction with monocyte-derived dendritic cells: An ex-vivo study

Bahrami, Armina Alagheband; Bandehpour, Mojgan; Kazemi, Bahram; Bozorgmehr, Mahmood; Mosaffa, Nariman; Chegeni, Rouzbeh

doi:10.1016/j.humimm.2020.02.010

Cited by 3 publications

(3 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PreHevbrio received FDA approval in November 2021 in the US, followed by EU approval in April 2022, and Canadian approval in December 2022 [ 97 ]. Similarly, Bahrami et al explored a novel fusion plasmid DNA vaccine, demonstrating significantly higher anti-HBsAg titers than the standard HBV vaccine [ 112 ].…”

Section: Hepatitis B Vaccines: Evolution and Effectivenessmentioning

confidence: 99%

See 1 more Smart Citation

Global Perspectives on the Hepatitis B Vaccination: Challenges, Achievements, and the Road to Elimination by 2030

Al-Busafi,

Alwassief

2024

Vaccines

View full text Add to dashboard Cite

Annually, more than 1.5 million preventable new hepatitis B (HBV) infections continue to occur, with an estimated global burden of 296 million individuals living with chronic hepatitis B infection. This substantial health challenge results in over 820,000 annual deaths being attributed to complications such as liver cirrhosis and hepatocellular carcinoma (HCC). The HBV vaccination remains the cornerstone of public health policy to prevent chronic hepatitis B and its related complications. It serves as a crucial element in the global effort to eliminate HBV, as established by the World Health Organization (WHO), with an ambitious 90% vaccination target by 2030. However, reports on global birth dose coverage reveal substantial variability, with an overall coverage rate of only 46%. This comprehensive review thoroughly examines global trends in HBV vaccination coverage, investigating the profound impact of vaccination on HBV prevalence and its consequences across diverse populations, including both high-risk and general demographics. Additionally, the review addresses the essential formidable challenges and facilitating factors for achieving WHO’s HBV vaccination coverage objectives and elimination strategies in the coming decade and beyond.

show abstract

Section: Hepatitis B Vaccines: Evolution and Effectivenessmentioning

confidence: 99%

“…Administering an HBV vaccination orally offers numerous theoretical benefits, such as increased convenience, potentially reduced side effects, and enhanced cost-effectiveness [ 112 ]. However, formidable challenges hinder its progress.…”

Section: Hepatitis B Vaccines: Evolution and Effectivenessmentioning

confidence: 99%

Global Perspectives on the Hepatitis B Vaccination: Challenges, Achievements, and the Road to Elimination by 2030

Al-Busafi,

Alwassief

2024

Vaccines

View full text Add to dashboard Cite

show abstract

“…PreHevbrio received FDA approval in November 2021 in the US, followed by EU approval in April 2022, and Canadian approval in December 2022 [97]. Similarly, Bahrami et al explored a novel fusion plasmid DNA vaccine, demonstrating significantly higher anti-HBsAg titers than the standard HBV vaccine [112].…”

Section: Improving Vaccine Immunogenicitymentioning

confidence: 99%

Global Perspectives on Hepatitis B Vaccination: Challenges, Achievements, and the Road to Elimination by 2030

Al-Busafi,

Alwassief

2024

Preprint

View full text Add to dashboard Cite

Annually, more than 1.5 million preventable new hepatitis B (HBV) infections continue to occur, with an estimated global burden of 296 million individuals living with chronic hepatitis B infection. This substantial health challenge results in over 820,000 annual deaths attributed to complications such as liver cirrhosis and hepatocellular carcinoma (HCC). HBV vaccination remains the cornerstone of public health policy to prevent chronic hepatitis B and its related complications. It serves as a crucial element in the global effort to eliminate HBV, as established by the World Health Organization (WHO), with an ambitious 90% vaccination target by 2030. However, reports on global birth dose coverage reveal substantial variability, with an overall coverage rate of only 46%. This comprehensive review thoroughly examines global trends in HBV vaccination coverage, investigating the profound impact of vaccination on HBV prevalence and its consequences across diverse populations, including both high-risk and general demographics. Additionally, the review addresses the formidable challenges and facilitating factors essential for achieving WHO's HBV vaccination coverage objectives and elimination strategies in the coming decade and beyond.

show abstract

Confirmation of candidates identified by reverse vaccinology in animal models or other immunogenicity assays

de Oliveira Matos,

Santos Dantas,

Silva-Sales

et al. 2024

Reverse Vaccinology

View full text Add to dashboard Cite

Assessment of a poly-epitope candidate vaccine against Hepatitis B, C, and poliovirus in interaction with monocyte-derived dendritic cells: An ex-vivo study

Cited by 3 publications

References 41 publications

Global Perspectives on the Hepatitis B Vaccination: Challenges, Achievements, and the Road to Elimination by 2030

Global Perspectives on the Hepatitis B Vaccination: Challenges, Achievements, and the Road to Elimination by 2030

Global Perspectives on Hepatitis B Vaccination: Challenges, Achievements, and the Road to Elimination by 2030

Confirmation of candidates identified by reverse vaccinology in animal models or other immunogenicity assays

Contact Info

Product

Resources

About